PMID- 19360864
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20181201
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 74
IP  - 3
DP  - 2009 Sep 1
TI  - Multicenter randomized trial of facilitated percutaneous coronary intervention 
      with low-dose tenecteplase in patients with acute myocardial infarction: the 
      Athens PCI trial.
PG  - 398-405
LID - 10.1002/ccd.22009 [doi]
AB  - OBJECTIVES: To examine the safety and efficacy of low-dose tenecteplase, 
      administered before facilitated percutaneous coronary intervention (PCI) to 
      restore Thrombolysis In Myocardial Infarction (TIMI) grade 2 or 3 blood flow in 
      the infarct related artery (IRA) in patients with ST elevation myocardial 
      infarction (STEMI) scheduled to undergo PCI with a shortest anticipated delay of 
      30 min. BACKGROUND: PCI preceded by administration of glycoprotein IIb/IIIa 
      inhibitors, full-dose thrombolytics, or both, is associated with no benefit or a 
      higher incidence of adverse events than PCI alone. METHODS: Patients with STEMI < 
      6 hr in duration were randomly assigned to PCI preceded by tenecteplase, 10 mg 
      (facilitated PCI group, n = 143) versus standard PCI (control group, n = 141). 
      All patients received aspirin and unfractionated heparin (70 IU/kg bolus) at time 
      of randomization. Both groups received IIb/IIIa inhibitors in the catheterization 
      laboratory and for at least 20 hr after PCI. RESULTS: The median door-to-balloon 
      time was 122 min (91-175) in the facilitated PCI versus 120 min (89-175) in the 
      control group. IRA patency on arrival in the catheterization laboratory was 59.5% 
      in the facilitated PCI (24% TIMI-2, 35% TIMI-3), versus 37% in the control (8% 
      TIMI-2, 29% TIMI-3) group (P = 0.0001). During hospitalization, 9 patients (6%) 
      died in the facilitated PCI versus 5 patients (3.5%) in the control group (P = 
      0.572). A single patient in the facilitated PCI group suffered a non-fatal 
      ischemic stroke. CONCLUSIONS: Facilitated PCI with low-dose tenecteplase in 
      patients presenting with STEMI was associated with a high IRA patency rate before 
      PCI.
CI  - 2009 Wiley-Liss, Inc.
FAU - Kanakakis, John
AU  - Kanakakis J
AD  - Department of Clinical Therapeutics, University of Athens School of Medicine, 
      Athens, Greece.
FAU - Nanas, John N
AU  - Nanas JN
FAU - Tsagalou, Eleftheria P
AU  - Tsagalou EP
FAU - Maroulidis, George D
AU  - Maroulidis GD
FAU - Drakos, Stavros G
AU  - Drakos SG
FAU - Ntalianis, Argirios S
AU  - Ntalianis AS
FAU - Tzoumele, Panagiotis
AU  - Tzoumele P
FAU - Skoumbourdis, Emmanuel
AU  - Skoumbourdis E
FAU - Charbis, Panagiotis
AU  - Charbis P
FAU - Rokas, Stylianos
AU  - Rokas S
FAU - Anastasiou-Nana, Maria
AU  - Anastasiou-Nana M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - R16CO5Y76E (Aspirin)
RN  - WGD229O42W (Tenecteplase)
SB  - IM
CIN - Catheter Cardiovasc Interv. 2009 Sep 1;74(3):406-7. PMID: 19681117
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary/adverse effects/mortality
MH  - Anticoagulants/administration & dosage
MH  - Aspirin/administration & dosage
MH  - Combined Modality Therapy
MH  - Coronary Angiography
MH  - Coronary Circulation
MH  - Drug Administration Schedule
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage/adverse effects
MH  - Greece
MH  - Heparin/administration & dosage
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/drug therapy/mortality/physiopathology/*therapy
MH  - Patient Transfer
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
MH  - Tenecteplase
MH  - *Thrombolytic Therapy/adverse effects/mortality
MH  - Time Factors
MH  - Tissue Plasminogen Activator/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Vascular Patency
EDAT- 2009/04/11 09:00
MHDA- 2009/10/30 06:00
CRDT- 2009/04/11 09:00
PHST- 2009/04/11 09:00 [entrez]
PHST- 2009/04/11 09:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - 10.1002/ccd.22009 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2009 Sep 1;74(3):398-405. doi: 10.1002/ccd.22009.